RasCase^®

Rasburicase Injection
(r-DNA origin) 1.5mg

Sayre Therapeutics offers clinicians an FDA approved option to manage Tumor Lysis Syndrome.

• Indication: FDA approved for the prevention and treatment of Tumor Lysis Syndrome (TLS).
• Formulation: Rasburicase Injection 1.5 mg for Intra venous administration.
• RasCase^®is
  • An offering for haematologists and medical oncologists to manage TLS.
  • Backed by robust evidence from International trials and an Indian Phase III trial with 100 patients published in Indian Journal of Cancer.
• What is TLS ?
  • A condition in which tumour cells release their content into bloodstream either spontaneously or in response to chemotherapy.
  • Most common in rapidly growing haematologic malignancies but has been reported in virtually every cancer type.
  • Prevention is the key as management can be challenging.